ALSO READPiramal in JV talks with CDPQ arm for realty PE fund Rs 84-lakh-crore housing bonanza attracts Piramal loan bet Piramal Enterprises' bets on Shriram group pay off Piramal Finance lends Rs 1,100 crore to real-estate developer Embassy Group Piramal Finance enters auto space, invests Rs 565 cr in two component cos
Total consolidated income from operations also rose to Rs 2,337.91 crore during the quarter under review as against Rs 1,829.23 crore in the same period a year ago, up 27.80%.
"We continue to maintain the strong focus on quality, compliance and risk mitigation across our businesses. We remain committed to deliver improved business performance and create sustainable long term value for all our stakeholders," Piramal Enterprises Chairman Ajay Piramal said.
During the quarter, pharma segment delivered revenues of Rs 917.85 crore, as compared to Rs 872.18 crore in Q1 FY2017.
Revenue growth from healthcare marginally declined to Rs 251.98 crore, during the quarter as against Rs 269.28 crore in the year-ago period, primarily due to shifting of existing business for the quarter to the next quarter and shift in timing of renewal of few annual contracts, the company said.
Income from financial services was 70.9% higher at Rs 1,084.24 crore during the quarter as against Rs 634.76 crore.
The stock was trading at Rs 2,957.50 on BSE up at 0.28%.